PTC Therapeutics
PTCTPTC Therapeutics is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines for rare disorders.
Earnings
Q3 2026 report
October 29, 2026Next report
Date not yet announcedFinancials
Q3 2026Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines for rare disorders. The company leverages a specialized scientific platform and global commercial infrastructure to address high unmet medical needs in neurology and metabolism. Its core value proposition lies in advancing a diversified pipeline of transformative therapies, including gene therapies and small molecule treatments, for both pediatric and adult populations.
A leading player in the rare disease space with a first-of-its-kind gene therapy for AADC deficiency and a significant commercial presence in the DMD market.
FAQ
- What is PTC Therapeutics's market cap?
- PTC Therapeutics (PTCT) has a market capitalization of $5.4B and trades on NASDAQ.
- What is PTC Therapeutics's revenue and profitability?
- PTC Therapeutics generated $1.2B in trailing twelve-month revenue, representing a net margin of 42.3%. Gross margin stands at 96.0%. The latest reported period is Q3 2026.
- Who are PTC Therapeutics's competitors?
- PTC Therapeutics's key competitors include Edgewise Therapeutics, Inc. Common Stock, Entrada Therapeutics, Inc. Common Stock, Sarepta Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does PTC Therapeutics partner with?
- PTC Therapeutics's notable partners include Akcea Therapeutics, Inc., Ionis Pharmaceuticals, Inc..
- Where is PTC Therapeutics headquartered?
- PTC Therapeutics is headquartered in United States of America and employs approximately 995 people. It has been publicly traded since 2013.
